Chinese Journal of Pharmacovigilance ›› 2016, Vol. 13 ›› Issue (8): 476-481.
Previous Articles Next Articles
LI Xiao-yu, CHAI Qian-wen, TIAN De-long, YANG Yue*
Received:
2016-09-14
Revised:
2016-09-14
Online:
2016-08-20
Published:
2016-09-14
CLC Number:
LI Xiao-yu, CHAI Qian-wen, TIAN De-long, YANG Yue. Research on USA and EU Regulations of Post-approval Drug Manufacturing Changes[J]. Chinese Journal of Pharmacovigilance, 2016, 13(8): 476-481.
[1] ICH.GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS Q7(Current Step 4version )[S/OL].(2000-11-10)[2016-06-14].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/ Step4/Q7_Guideline.pdf. [2] ICH.PHARMACEUTICAL QUALITY SYSTEM Q10 (Current Step 4 version ) [S/OL].(2008-06-04)[2016-06-14].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf. [3] ICH. Final Concept Paper Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management[EB/OL].(2014-07-28)[2016-06-14].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q12/Q12_Final_Concept_Paper_July_2014.pdf. [4] EMA. COMMISSION REGULATION (EC) No 1234/2008of concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products [S/OL]. (2008-11-24)[2016-06-14].http://ec.europa.eu/health/files/eudralex/vol-1/reg_2008_1234_cons_2012-11-02/reg_2008_1234_cons_2012-11-02_en.pdf. [5] USA.21 USC 356a: Manufacturing changes[S/OL]. (2016-01-30) [2016-06-14].http://uscode.house.govviewxhtml?req=granuleid:USC-prelim-title21-section356a&num=0&edition=prelim. [6] FDA.CODEOF FEDERAL REGULATIONSTITLE 21 314.70(10) [S/OL].(2014-01-01)[2016-06-14].http://www.gpo.gov/fdsys/pkg/CFR-2014-title21-vol5/pdf/CFR-2014-title21-vol5.pdf. [7] EMA. Guidelines on the details of the various categories of variations,on the operation of the procedures laid down in Chapters II, IIa, III and IV of Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products and on the documentation to be submitted pursuant to those procedures[S/OL].(2013-02-08)[2016-06-14].http://ec.europa.eu/health/files/eudralex/vol-1/c_2013_223/c_2013_2804_en.pdf. [8] FDA. North Bethesda, MD. Supplement Review Process 2012 GPhA/FDA Fall Technical Conference[EB/OL]. (2012-10-03) [2016-06-14].http://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm368222.pdf. [9] FDA. Guidance for Industry CMC Post-approval Manufacturing Changes To Be Documented in Annual Reports [S/OL]. (2014-03)[2016-06-14].http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM217043.pdf. [10] EMA. Industry European Workshop on Lifecycle Management Application Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols[EB/OL] .(2015-11-17)[2016-06-14].http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2015/11/WC500196662.pdf. [11] ICH. Final Concept Paper Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management[S/OL]. (2014-07-28)[2016-06-14].http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q12/Q12_Final_Concept_Paper_July_2014.pdf. [12] EMA.Questions and answers on post approval change management protocols[S/OL] .(2012-03-30)[2016-06-14].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/04/WC500125400.pdf. [13] FDA.Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information Guidance for Industry DRAFT GUIDANCE[S/OL].(2016-04)[2016-06-14].http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm496611.pdf. [14] FDA.GPhA Fall Technical Conference.QbD Status Update Generic Drugs[EB/OL] .(2011-10-03)[2016-06-14].http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelope-dandapproved/approvalapplications/abbreviatednewdrugapplicatio-nandagenerics/ucm292666.pdf. [15] 北京大学药物信息与工程研究中心翻译.药品注册批准前检查—美国药品监管法规核心理念概述(第2版)[M].北京:北京大学医学出版社,2011:15-16. [16] 吴晓明,郑强. 原料药产地变更对药品质量的影响[J]. 中国新药杂志,2014,23(12):1382-1389. [17] CFDA.总局关于辽宁玉皇药业有限公司哈高科白天鹅药业集团有限公司违法生产注射用促肝细胞生长素的通告[EB/OL].(2016-03-15)[2016-06-14]. http://www.sda.gov.cn/WS01/CL0087/147198.html. [18] CFDA.国家食品药品监督管理总局关于停止进口脑蛋白水解物注射液等4个药品的公告(2016年第13号)[EB/OL].(2016-01-22)[2016-06-14].http://www.sda.gov.cn/WS01/CL0087/142820.html. [19] CFDA.国家食品药品监督管理总局药品审评中心2015年度药品审评报告[EB/OL].(2016-03-03)(2016-06-14). http://www.cde.org.cn/news.do?method=viewInfoCommon&id=313528. [20] CFDA.(国产)药品补充申请审[EB/OL].(2006-02-20)[2016-06-14]. http://www.sda.gov.cn/WS01/CL0372/24058.html. [21] CFDA.进口(含港、澳、台)药品补充申请审核[EB/OL].(2012-11-05)[2016-06-14].http://www.sda.gov.cn/WS01/CL0371/76181.html. [22] CFDA.(国产)直接接触药品的包装材料和容器补充申请审核[EB/OL].(2006-02-20)[2016-06-14]. http://www.sda.gov.cn/WS01/CL0372/24070.html. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[3] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
[4] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[5] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
[6] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
[7] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[8] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
[9] | LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006. |
[10] | ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan. Comparison standard terminology for pharmaceutical dose forms [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910. |
[11] | ZHAO Xuan, GUO Jing, CHEN Ning, MEI Long, ZHENG Tingting, ZHANG Lifang, ZHANG Wei. Discuss the safety management of medical toxic drugs in medical institutions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 705-708. |
[12] | SHA Mingquan, ZHANG Yawei, ZHOU Hongjie, WEN Baoshu. A comparative progress and prospect for drug technological guidances system in China [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1045-1049. |
[13] | SONG Mingyue, ZHANG Ran, WU Zhiang. Influencing factors of quality risk management of drug recall in China [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090. |
[14] | GENG Kexin, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, SA Rina, JIANG Hao, ZOU Lina. Safety of traditional Chinese medicine among lactating women and pharmacovigilance [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 908-912. |
[15] | ZHANG Qingxia, JIANG Yongxian, DONG Yuexin, XIAN Ying, YAN Suying. Risk analysis and precautions related to storage conditions specified in package inserts of western medicines in a hospital [J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 913-918. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||